Alpha Teknova earnings release, May 6, 2026

Alpha Teknova, Inc. (TKNO) · Form 8-K, Item 2.02 · Filed · SEC filing

Teknova Reports First Quarter 2026 Financial Results

First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year

Company reaffirms 2026 revenue guidance of $42-44 million

HOLLISTER, Calif., May 6, 2026 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2026.

“We had a great start to 2026,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “The substantial investments we’ve made since 2021, combined with an improved market backdrop, position Teknova for sustainable above-market growth over the next couple years, particularly as our Clinical Solutions customers advance their therapies and diagnostics towards commercialization.”

Matt Lowell, Teknova’s Chief Financial Officer, added, “We delivered strong financial results in the first quarter 2026 compared to 2025, including 13% revenue growth and significant improvements in Adjusted EBITDA and Free Cash Outflow. We believe the Company is well positioned to maintain its momentum. We therefore reiterate our 2026 revenue guidance of $42-44 million and continue to anticipate full-year Free Cash Outflow of less than $10 million,” he explained.

Corporate and Financial Updates

• First quarter 2026 total revenue of $11.1 million, up 13% compared to $9.8 million for the first quarter 2025

• Total cash and short-term investments were $17.8 million and total borrowings were $13.2 million at the end of the first quarter 2026

Revenue for the First Quarter 2026

First Quarter 2026 Financial Results

Total revenue for the first quarter 2026 was $11.1 million, up 13% compared to $9.8 million in the first quarter 2025. Lab Essentials revenue was $8.4 million in the first quarter 2026, up 3% compared to $8.1 million in the first quarter 2025. Clinical Solutions revenue was $2.1 million in the first quarter 2026, up 85% compared to $1.2 million in the first quarter 2025.

Gross profit for the first quarter 2026 was $3.8 million, compared to $3.0 million in the first quarter 2025. Gross margin for the first quarter 2026 was 34.2%, compared to 30.7% in the first quarter 2025. The increase in gross margin was primarily driven by higher revenue.

Operating expenses for the first quarter 2026 were $8.1 million, compared to $8.0 million in the first quarter 2025. The increase was primarily driven by higher spending in sales and marketing, resulting from higher headcount and increased marketing expenses, partially offset by lower general and administrative expenses attributable to lower stock-based compensation expense and professional fees.

Net loss for the first quarter 2026 was $4.6 million, or negative $0.08 per diluted share, compared to $4.6 million, or negative $0.09 per diluted share, for the first quarter 2025. Adjusted EBITDA for the first quarter 2026 was negative $2.0 million, compared to negative $2.5 million for the first quarter 2025.

Cash used in operating activities for the first quarter 2026 was $3.4 million, compared to $4.1 million of cash used in operating activities for the first quarter 2025. Free Cash Outflow was $3.6 million for the first quarter 2026, compared to $4.3 million for the first quarter 2025.

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

Reaffirms 2026 Outlook

Teknova reaffirms its fiscal 2026 outlook for revenue and Free Cash Outflow. The Company continues to anticipate total revenue of $42 million to $44 million for the fiscal year ending December 31, 2026 (“2026”). The Company also anticipates Free Cash Outflow of less than $10 million for 2026.

Upcoming Investor Conference Attendance

Craig-Hallum Institutional Investor Conference (Minneapolis, MN)

Thursday, May 28, 2026

William Blair Growth Stock Conference (Chicago, IL)

Thursday, June 4, 2026

Conference Call and Webcast

Teknova will host a webcast and conference call on Wednesday, May 6, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the

Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

Non-GAAP Financial Measures... (truncated)ed EBITDA and (b) Free Cash Flow (Outflow).

Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that Teknova does not consider representative of its ongoing operating performance.

Teknova defines Free Cash Flow (Outflow) as cash provided by (used in) operating activities less purchases of property, plant, and equipment.

Teknova provides Adjusted EBITDA and Free Cash Flow (Outflow) in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in Teknova’s industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in Teknova’s operating results because they exclude items that are not indicative of Teknova’s core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

Financial statements

Income Statement

For the Three Months Ended March 31, — Revenue for the First Quarter 2026 (in thousands)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Lab Essentials8,3958,117
Clinical Solutions2,1451,162
Other537516
Total revenue11,0779,795

Income Statement

For the Three Months Ended March 31, — (In thousands, except share and per share data)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Revenue11,0779,795
Cost of sales7,2936,788
Gross profit3,7843,007
Operating expenses:Research and development609552
Operating expenses:Sales and marketing2,1281,640
Operating expenses:General and administrative5,0585,492
Operating expenses:Amortization of intangible assets287287
Operating expenses:Total operating expenses8,0827,971
Operating expenses:Loss from operations-4,298-4,964
Other (expenses) income, netInterest expense, net-219-144
Other (expenses) income, netOther adjustment to loan exit fee485
Other (expenses) income, netOther income9
Other (expenses) income, netTotal other (expenses) income, net-210341
Other (expenses) income, netLoss before income taxes-4,508-4,623
Other (expenses) income, netProvision for income taxes4722
Other (expenses) income, netNet loss-4,555-4,645
Other (expenses) income, netNet loss per share—basic and diluted-0.08-0.09
Other (expenses) income, netWeighted average shares used in computing net loss per share—basic and diluted53,606,27853,421,533

Income Statement

For the Three Months Ended March 31, — (In thousands) (in thousands)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Net loss – as reported-4,555-4,645
Add back:Interest expense, net-219-144
Add back:Provision for income taxes4722
Add back:Depreciation expense1,2891,293
Add back:Amortization of intangible assets287287
Add back:EBITDA-2,713-2,899
Other and non-recurring expenses:Stock-based compensation expense695852
Other and non-recurring expenses:Other adjustment to loan exit fee-485
Other and non-recurring expenses:Adjusted EBITDA-2,018-2,532

Balance Sheet

As of March 31, — (In thousands) (in thousands)

As of March 31, – 2026As of December 31, – 2025
Current assets:Cash and cash equivalents4,3065,912
Current assets:Short-term investments, held -to-maturity13,47815,426
Current assets:Accounts receivable, net5,6724,618
Current assets:Inventories, net6,8747,054
Current assets:Prepaid expenses and other current assets1,3441,501
Current assets:Total current assets31,67434,511
Current assets:Property, plant, and equipment, net40,52441,733
Current assets:Operating right-of-use lease assets13,60814,112
Current assets:Intangible assets, net11,65611,943
Current assets:Other non-current assets1,1951,285
Current assets:Total assets98,657103,584
Current liabilities:Accounts payable1,6181,378
Current liabilities:Accrued liabilities3,3634,283
Current liabilities:Current portion of operating lease liabilities1,9151,876
Current liabilities:Total current liabilities6,8967,537
Current liabilities:Deferred tax liabilities925879
Current liabilities:Long-term debt, net13,17013,123
Current liabilities:Long-term operating lease liabilities12,74213,270
Current liabilities:Total liabilities33,73334,809
Stockholders’ equity:Common stock11
Stockholders’ equity:Additional paid-in capital205,268204,564
Stockholders’ equity:Accumulated deficit-140,345-135,790
Stockholders’ equity:Total stockholders’ equity64,92468,775
Stockholders’ equity:Total liabilities and stockholders’ equity98,657103,584

Balance Sheet

For the Three Months Ended March 31, — (In thousands) (in thousands)

For the Three Months Ended March 31, – 2026For the Three Months Ended March 31, – 2025
Operating activities:Net loss-4,555-4,645
Adjustments to reconcile net loss to net cash used in operating activities:Bad debt expense745
Adjustments to reconcile net loss to net cash used in operating activities:Inventory reserve413437
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization1,5761,580
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation695852
Adjustments to reconcile net loss to net cash used in operating activities:Deferred taxes4621
Adjustments to reconcile net loss to net cash used in operating activities:Accrued interest income on short-term investments-27-54
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of discount on short-term investments-87-184
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of debt financing costs4786
Adjustments to reconcile net loss to net cash used in operating activities:Other adjustment to loan exit fee-485
Adjustments to reconcile net loss to net cash used in operating activities:Non-cash lease expense1530
Changes in operating assets and liabilities:Accounts receivable-1,061-1,349
Changes in operating assets and liabilities:Inventories-233-209
Changes in operating assets and liabilities:Prepaid expenses and other current assets157-4
Changes in operating assets and liabilities:Other non-current assets9063
Changes in operating assets and liabilities:Accounts payable330740
Changes in operating assets and liabilities:Accrued liabilities-772-1,017
Full release

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to Teknova’s anticipated total revenue, including our expectations for 2026 revenue and Free Cash Outflow guidance, and other statements about Teknova’s business prospects, including about Teknova’s profitability, strategy of managing operating expenses, and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond Teknova’s control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, demand for Teknova’s products (including the potential delay to or pausing of customer orders); Teknova’s assessment of fundamental indicators of future demand across its target customer base; Teknova’s cash flows and revenue growth rate; Teknova’s supply chain, sourcing, manufacturing, and warehousing; inventory management; risks related to global economic and marketplace uncertainties, including those related to the conflicts in Ukraine and the Middle East; potential acquisitions and integration of other companies; and other factors discussed in the “Risk Factors” section of Teknova’s most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although Teknova believes that the expectations reflected in its forward-looking statements are reasonable, Teknova does not know whether its expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which Teknova makes only as of the date hereof, even if they are repeated by Teknova subsequently. Teknova does not intend and shall have no obligation to update, amend, or clarify these forward-looking statements, except as may be required under applicable securities laws.

Investor Contact

Matt Lowell

Chief Financial Officer matt.lowell@teknova.com

+1 831-637-1100

Media Contact

Jennifer Henry

Senior Vice President, Marketing jenn.henry@teknova.com

+1 831-313-1259

ALPHA TEKNOVA, INC.

Condensed Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

ALPHA TEKNOVA, INC.

Condensed Balance Sheets

(Unaudited)

(In thousands)

ALPHA TEKNOVA, INC.

Condensed Statements of Cash Flows

(Unaudited)

(In thousands)

ALPHA TEKNOVA, INC.

Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures

(Unaudited)

(In thousands)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Alpha Teknova earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.